Matches in SemOpenAlex for { <https://semopenalex.org/work/W2022887456> ?p ?o ?g. }
Showing items 1 to 66 of
66
with 100 items per page.
- W2022887456 endingPage "372" @default.
- W2022887456 startingPage "364" @default.
- W2022887456 abstract "Abstract. The present study aimed at 1) investigating the effect of a combined insulin + glipizide treatment on the metabolic control (HbA 1c levels) and insulin requirements (Biostator ® assessment) in ten non-obese Type-II diabetic patients with recent secondary failure to sulfonylureas; and 2) characterizing the relative contributions of changes in endogenous insulin secretion (C-peptide response) and insulin sensitivity (insulin-induced glucose disposal in clamped conditions) to this effect. The patients were treated in a randomized cross-over order with either insulin alone or insulin + glipizide (3 × 10 mg/day) during two periods averaging 6 weeks each. Mean HbA 1c levels were similar in both experimental conditions (8.2 ± 0.6 vs 7.9 ± 0.6%, NS). In fact, during the combined therapy, HbA 1c levels decreased in five subjects (from 8.6 ± 0.7 to 7.1 ± 0.5%; 'responders'), but not in the five others ('non-responders'); the 20-h Biostator insulin infusion was significantly decreased in the responders (29%; P < 0.05), but not in the non-responders. Basal (0.271 ± 0.086 vs 0.086 ± 0.017 nmol/l; P < 0.05) and post-glucagon (0.468 ± 0.121 vs 0.180 ± 0.060 nmol/l; P < 0.05) C-peptide plasma levels were significantly higher in the responders than in the non-responders; in addition, glipizide significantly increased basal C-peptide concentrations in the responders only (+ 68%; P < 0.05). The insulininduced glucose disposal was significantly increased by glipizide in the responders (+ 23%; P < 0.05), but not in the non-responders; however, this difference could be due to higher plasma free insulin levels (+ 37%; P < 0.02) during the clamp with glipizide in the responders who showed persistent C-peptide stimulation. Thus, combining glipizide with insulin seems to be useful only in Type-II diabetic patients who still have a significant endogenous insulin secretion capable of being stimulated by this compound." @default.
- W2022887456 created "2016-06-24" @default.
- W2022887456 creator A5039563874 @default.
- W2022887456 creator A5051572464 @default.
- W2022887456 creator A5077526534 @default.
- W2022887456 creator A5084616356 @default.
- W2022887456 date "1987-11-01" @default.
- W2022887456 modified "2023-10-15" @default.
- W2022887456 title "The addition of glipizide to insulin therapy in Type-II diabetic patients with secondary failure to sulfonylureas is useful only in the presence of a significant residual insulin secretion" @default.
- W2022887456 doi "https://doi.org/10.1530/acta.0.1160364" @default.
- W2022887456 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/3318259" @default.
- W2022887456 hasPublicationYear "1987" @default.
- W2022887456 type Work @default.
- W2022887456 sameAs 2022887456 @default.
- W2022887456 citedByCount "26" @default.
- W2022887456 countsByYear W20228874562012 @default.
- W2022887456 countsByYear W20228874562016 @default.
- W2022887456 crossrefType "journal-article" @default.
- W2022887456 hasAuthorship W2022887456A5039563874 @default.
- W2022887456 hasAuthorship W2022887456A5051572464 @default.
- W2022887456 hasAuthorship W2022887456A5077526534 @default.
- W2022887456 hasAuthorship W2022887456A5084616356 @default.
- W2022887456 hasConcept C126322002 @default.
- W2022887456 hasConcept C134018914 @default.
- W2022887456 hasConcept C2777180221 @default.
- W2022887456 hasConcept C2778024521 @default.
- W2022887456 hasConcept C2778563252 @default.
- W2022887456 hasConcept C2778875212 @default.
- W2022887456 hasConcept C2779306644 @default.
- W2022887456 hasConcept C2779555806 @default.
- W2022887456 hasConcept C2909524832 @default.
- W2022887456 hasConcept C555293320 @default.
- W2022887456 hasConcept C71924100 @default.
- W2022887456 hasConceptScore W2022887456C126322002 @default.
- W2022887456 hasConceptScore W2022887456C134018914 @default.
- W2022887456 hasConceptScore W2022887456C2777180221 @default.
- W2022887456 hasConceptScore W2022887456C2778024521 @default.
- W2022887456 hasConceptScore W2022887456C2778563252 @default.
- W2022887456 hasConceptScore W2022887456C2778875212 @default.
- W2022887456 hasConceptScore W2022887456C2779306644 @default.
- W2022887456 hasConceptScore W2022887456C2779555806 @default.
- W2022887456 hasConceptScore W2022887456C2909524832 @default.
- W2022887456 hasConceptScore W2022887456C555293320 @default.
- W2022887456 hasConceptScore W2022887456C71924100 @default.
- W2022887456 hasIssue "3" @default.
- W2022887456 hasLocation W20228874561 @default.
- W2022887456 hasLocation W20228874562 @default.
- W2022887456 hasOpenAccess W2022887456 @default.
- W2022887456 hasPrimaryLocation W20228874561 @default.
- W2022887456 hasRelatedWork W1964050512 @default.
- W2022887456 hasRelatedWork W1964422326 @default.
- W2022887456 hasRelatedWork W1976823253 @default.
- W2022887456 hasRelatedWork W2002744316 @default.
- W2022887456 hasRelatedWork W2075935248 @default.
- W2022887456 hasRelatedWork W2302924012 @default.
- W2022887456 hasRelatedWork W2777315381 @default.
- W2022887456 hasRelatedWork W3217278874 @default.
- W2022887456 hasRelatedWork W4229367634 @default.
- W2022887456 hasRelatedWork W4235685257 @default.
- W2022887456 hasVolume "116" @default.
- W2022887456 isParatext "false" @default.
- W2022887456 isRetracted "false" @default.
- W2022887456 magId "2022887456" @default.
- W2022887456 workType "article" @default.